pharma · Relapsing-Remitting Multiple Sclerosis · Spinal Muscular Atrophy
Biogen
Biogen clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 225 Binney Street, Cambridge, MA 02142, US
- Employees
- 7,534
- Programs
- 31
- Drugs
- 45
- Patents
- 25
Biogen projects
4 ClinicalTrials.gov programs sponsored by Biogen.
Biogen has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
283PD201
Biogen
Parkinson's Disease
1 trial -
299AR201
Biogen
Treatment of Late Isolated Microvascular Inflammation in Recipients of Kidney Transplants
1 trial -
EnEPC-CLI-01
Biogen
Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment.
1 trial -
Felzartamab
Biogen
Immunoglobulin A (IgA) Nephropathy
1 trial
Frequently asked questions
How many clinical projects does Biogen have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.